Treatment Related Undesirable Effects Reported in Multiple Myeloma Clinical Trial (Caelyx 30 mg/ m2 in combination with bortezomib every 3 weeks) by Severity, MedDRA System Organ Class and Preferred Term Very Common (≥ 1/ 10); Common (≥ 1/ 100, < 1/ 10); Uncommon (≥ 1/ 1,000, < 1/ 100) CIOMS III AE by body system